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Dear Editor(s): 
We would like to submit the manuscript titled “Evaluation of the Technical Variations and 
the Suitability of a Hydrophilic Interaction Liquid Chromatography-High Resolution Mass 
Spectrometry (ZIC-pHILIC-Exactive Orbitrap) for Clinical Urinary Metabolomics Study” to 
Journal of Chromatography B. 
Currently LC-MS based untargeted metabolite profiling is the most widely used strategy for 
biomarker discovery in clinical metabolomics. However, it is the fact that the biomarkers 
reported in one research study are often invalid in another using different analytical 
method. Poor method reliability and robustness is considered as one of the reasons, but 
only a few investigation studies have been reported in respect of this concern and most of 
them used reversed phase chromatography. 
As following up our previous studies on development and optimisation of Hydrophilic 
Interaction Liquid Chromatography-High Resolution Mass Spectrometry (HILIC-HRMS) for 
untargeted metabolite profiling, here using a series of human urine samples, we 
investigated the technical variations of this method and its suitability for supervised 
multivariate analysis  
By comparison of LC-MS data generated by the samples (injections) prepared in different 
ways, we observed that the technical variation introduced by sample preparation was more 
significant than the current HILIC-HRMS method. Therefore, it is necessary to prepare and 
measure multiple QC samples with the real samples for assessment of data deviations 
introduced in sample preparation. By using a series of human urine samples spiked with 
isotope labelled amino acids at varied concentrations, to the best of our knowledge, at the 
first time, we demonstrated the suitability of a LC-MS method for untargeted metabolite 
profiling in supervised multivariate analysis ((e.g. Orthogonal Partial Linear Square: OPLS). 
The robustness of the current HILIC method was evaluated by manipulation of several key 
LC parameters that may affect the reproducibility in practical use for long term/batch-to-
batch analysis. Some influential parameters were determined by Principal Component 
Analysis (PCA) of the retention times obtained under varied LC conditions. One of our 
important findings is the high reproducibility among different columns in chromatographic 
Cover Letter
performance of this polymer based zwtterionic stationary phase in HILIC mode, which allows 
column replacement for high sample throughput analysis among multiple batches. 
Based on the observation in this study, this HILIC-HRMS (ZIC-pHILIC coupled with Exactive 
Orbitrap) method has been demonstrated to be reliable and suitable for biomarker 
discovery in clinical metabolomics.  
Regards 
Tong Zhang 
22/01/16 
Dear Editor(s): 
Please find our replies to the reviewers’ comments below in red. 
 
Regards 
 
Tong Zhang 
 
Reviewer #1: Experimental methods were not accessible for review from author's prior publications.  
I suggest that the LC and MS experimental conditions be listed for convenience of the reader. 
For convenience the LC-MS conditions have been added to the current paper. 
 
 
Reviewer #3: In this paper Zhang and Watson expand upon the excellent work performed on Zic-
pHILIC chromatography published by validating the robustness of the assay when analyzing urine. 
This work is well referenced and well written. Several issues of note: 
1. I had a difficult time reading the figures due to poor graphics resolution in the pdf. 
All the original figures are made with high resolution. The poor resolution was caused by the 
conversion to the PDF format when the figures were uploaded to the JCB website. 
 
2. I would like to see a spread sheet of the analysis order to fully evaluate the robustness testing, as 
it is now I am not absolutely sure of how to evaluate the data. 
Good point, as suggested Table 1 has been remade and the relevant description has also been added 
into section 2.3.  
  
3. I would like to see a 5 by 5 analysis performed using the final assay conditions. That is run 25 
samples total, 5 samples a day, 5 days in a row to determine robustness testing. 
We don’t think the assessment of intermediate precision in this way is applicable to metabolomics 
studies which are run continuously over perhaps 5 days rather than batch-wise and are thus open 
ended. Thus any degradation in performance comes from cumulative effects such as build-up of 
matrix components in the background or the LC-MS source becoming dirty. The method for 
controlling fall off in performance during batch runs is the use of a pooled sample which is run at 
intervals throughout the run.  The current study was aimed at assessing the robustness of the 
method in withstanding variations in factors such as column temperature, mobile phase pH and the 
variation in column batch which occurs between batches which might be run weeks or months 
apart.  The good intermediate precision of this HILIC-HRMS method has been demonstrated in our 
previous publications using the data from pooled QC samples run with the real samples. Thus the 
purpose of the current paper is to recommend the method at the level of reproducibility i.e. it could 
be adopted by another laboratory without loss of performance.  
Response to Reviews
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Abstract 20 
Although many hydrophilic interaction liquid chromatography-high resolution mass 21 
spectrometry (HILIC-HRMS) methods have been developed and applied for untargeted 22 
metabolite profiling in clinical metabolomics, according to the literature, the suitability of 23 
these HILIC-HRMS methods has not been fully evaluated with respect to their performance 24 
when they are subjected to statistical analysis. In this study, using a series of human urine 25 
samples we investigated the effect of technical variations on multivariate and univariate 26 
analysis of the data collected using a previously developed HILIC-HRMS method for 27 
untargeted urinary metabolite profiling in clinical metabolomics. The technical variation 28 
introduced by sample preparation was more significant than that produced by the HILIC-29 
HRMS method. By using an orthogonal partial least squares (OPLS) model, subtle fold-30 
changes were accurately measured in the urine samples spiked with 13C and 15N isotope 31 
labelled amino acids at different concentrations. The robustness of this HILIC method was 32 
also evaluated by analysing the obtained data from a single urine sample following 33 
manipulation of several primary LC parameters. High reproducibility in the chromatographic 34 
performance of three ZIC-pHILIC columns with different batch numbers indicated the 35 
reliability of the polymer based zwitterionic stationary phase allowing column replacement 36 
without compromising the performance of the method.  37 
 38 
Keywords: clinical metabolomics; Hydrophilic Interaction Liquid Chromatography-High 39 
Resolution Mass Spectrometry (HILIC-HRMS); untargeted metabolite profiling; technical 40 
variation; isotope labelled amino acids  41 
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1 Introduction 42 
In clinical metabolomics, untargeted metabolite profiling is designed for identification and 43 
comparative analysis of hundreds or thousands of metabolites in clinical samples e.g. urine, 44 
blood and tissues. [1-6] Associated with multivariate analysis (MVA), it offers the 45 
opportunity to compare/differentiate the metabolic fingerprints of clinical samples and to 46 
discover individual biomarker candidates for identifying particular pathological states. By 47 
following this strategy, untargeted metabolite profiling of biofluid samples has been used 48 
for the development of new techniques potentially applicable in clinical use, such as disease 49 
diagnosis and prognosis, therapeutic treatment evaluation and disease screening. [1-6] 50 
However, up until now no metabolic biomarkers have been reported for practical use in 51 
clinics, with the exception perhaps of a method for the typing of the rare conditions 52 
xanthuria types I and II,[7, 8] especially for common diseases such as cancer. This results 53 
from the fact that poor reproducibility has been reported for biomarkers between research 54 
groups where often insufficient cohorts have been involved in these studies.[9, 10] For 55 
instance, sarcosine was reported as a biomarker metabolite correlated with prostate cancer 56 
progression in 2009, [11] but this was followed by many contradictory results found by 57 
different research groups using different analytical methods.[12] Besides vague 58 
experimental designs and inappropriate data analysis/interpretation, an unreliable and/or 59 
unsuitable analytical method can be considered as one of the principal reasons for poor 60 
biomarker reproducibility.[13, 14]  61 
Nowadays, Mass Spectrometry (MS) coupled with Liquid Chromatography (LC) is the most 62 
widely employed analytical platform for untargeted metabolite profiling of biological 63 
samples.[2, 3, 6, 15] Many LC-MS method development and comparison studies have been 64 
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reported.[16-21] In order to approach the maximum metabolome coverage, the number of 65 
detected metabolites is of the greatest concern in these studies. The quality of the 66 
chromatographic signals should be addressed because poor/irregular chromatographic 67 
peaks for metabolites could lead to false outcomes in data processing which can be easily 68 
overlooked by bioinformaticians and biologists who may be unaware of the impact of 69 
chromatography on data quality.[17] The other critical point, especially for clinical 70 
metabolomics, is the LC-MS method stability for long-term experiments (intra- and inter-71 
batch) and its robustness in withstanding to small changes in LC-MS conditions which are 72 
inevitable for batch-to-batch analysis of samples. Such changes can result from factors such 73 
as LC column replacement, variations in mobile phase composition, the accuracy of the 74 
gradient formation by the HPLC and MS system maintenance. Although some data 75 
processing algorithms can be applied for reducing the deviations introduced in data 76 
acquisition, the quality of the raw data should be addressed as a priority, thus the technical 77 
variations caused by sample preparation and data acquisition in an analytical method should 78 
be evaluated for determination of its reliability in clinical metabolomics studies. 79 
Recently a few studies have been reported with respect to the stability of LC-MS platforms 80 
for untargeted metabolite profiling using unsupervised MVA (e.g. Principal Component 81 
Analysis: PCA) of Quality Control (QC) samples/injections.[18, 22-25] In real clinical 82 
metabolomics studies, however, supervised MVA (e.g. Orthogonal Partial Linear Squares-83 
Discriminant Analysis: OPLS-DA) is much more effective for uncovering biomarkers due to 84 
the large matrix effect of clinical samples which is more likely orthogonal to the genuine 85 
pathological changes in such samples. According to our literature review, no studies have 86 
demonstrated the suitability of an LC-MS method in such circumstances by using supervised 87 
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MVA. In addition, there is increasing evidence that hydrophilic interaction liquid 88 
chromatography (HILIC) is more advantageous than, or at least highly complementary to, 89 
reversed phase (RP) LC in untargeted polar metabolite profiling coupled with HRMS.[9, 26]. 90 
In our previous studies, we have systematically demonstrated the superiority of a HILIC-91 
HRMS (ZIC-pHILIC-Exactive Orbitrap) method in metabolite coverage and chromatographic 92 
performance for untargeted profiling of polar metabolites in biological samples.[16, 17] In 93 
this study, in order to further evaluate the reliability and suitability of this method for 94 
clinical metabolomics, evaluation tests were performed using a series of spiked samples 95 
prepared from one single urine sample and the generated LC-MS data were assessed by 96 
both unsupervised and supervised MVA (PCA and OPLS) as well as reproducibility in peak 97 
area and retention time for individual LC-MS signals. Several key LC parameters, which 98 
might potentially introduce systematic variation to the measurements between batches 99 
and/or laboratories, were also evaluated in order to test the robustness of the HILIC method.  100 
2 Material and methods  101 
2.1 Chemicals 102 
HPLC grade acetonitrile (ACN) was obtained from Fisher Scientific, UK. Ammonium 103 
carbonate, formic acid and ammonium hydroxide solution (28-30%) were purchased from 104 
Sigma-Aldrich, UK. HPLC grade water was produced by a Direct-Q 3 Ultrapure Water System 105 
from Millipore, UK. The standard mix of sixteen 13C and 15N isotope fully labelled amino 106 
acids (Electronic Supplementary Information.1: ESI.1) was purchased from Sigma-Aldrich, UK 107 
(487910-500mg) and a stock solution was prepared at the concentration of 1.5mg/ml in the 108 
mixture of ACN and water (1:1). Because this standard mixture was extracted from blue-109 
green algae, it is believed that it contains some other metabolites which are not heavy 110 
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isotope labelled. The stock solution was diluted 10 times with ACN only to prepare the 111 
solution (150µg/ml) named as dilution factor (DF) 1. This DF1 solution was further diluted 5, 112 
10, 15 and 20 times with ACN to obtain the solutions at the concentration of 30, 15, 10 and 113 
7.5µg/ml and correspondingly named as DF5, DF10, DF15 and DF20, respectively which 114 
were used as the ACN solutions required in the following urine sample preparation.   115 
2.2 Urine sample preparation 116 
One hundred millilitres of human urine was obtained with ethics permission from our 117 
previous study.[27] A series of samples were prepared from this single urine sample as 118 
schematically shown in Figure.1. The replicate samples were named in the following figures 119 
with the urine volumes used in the preparation or the dilution factors of isotope labelled 120 
amino acids in ACN (see Figure.1). After centrifugation at 10,000 RPM for 5 minutes the 121 
clear solutions were transferred into LC auto-sampler vials and randomly sequenced for the 122 
HILIC-HRMS experiment with QC injections (named as QCI) from a single 200-QC sample. 123 
Including blank injections this whole experiment lasted approximately 56 hours. For HILIC 124 
method robustness tests one single sample of QC-200 was used. 125 
2.3 HILIC-HRMS experiment 126 
The HILIC-HRMS experiments were carried out on a Dionex Ultimate 3000 HPLC system 127 
coupled with an Exactive (Orbitrap) mass spectrometer (Thermo Fisher Scientific, Germany). 128 
Three ZIC-pHILIC columns (150×4.6mm, 5µm) used in this study were purchased from 129 
HiChrom (Reading UK). For evaluation of the technical variations in this analytical method, 130 
all the HILIC-HRMS parameters were set to the values optimised in our previous studies [16, 131 
17] as described below: the mass scanning range was m/z 75–1200, the needle voltage was 132 
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4.5 kV in positive mode and -4.0 kV in negative mode, the capillary temperature was 320 °C 133 
and the sheath and auxiliary gas flow rates were 50 and 17 arbitrary units, respectively. The 134 
mobile phase used was 20 mM ammonium carbonate buffer (pH 9.2) (A) and pure ACN (B); the 135 
flow rate was 300 μl min−1. The gradient was programed as follows: 0 min 20% A 80% B to 136 
time 30 min 80% A 20% B 31 min 8 % B 36 min 8 % B 37 min 80% B  46 min 80% B. The 137 
injection volume was 10 μl and the sample tray temperature was controlled at 12 °C during 138 
the measurement.  139 
 For HILIC method robustness tests each primary LC parameter was examined at three levels 140 
and the manipulation is detailed in Table 1. Only one single parameter was changed under 141 
each condition with the others fixed at the standard settings and one blank injection was 142 
made for equilibration purpose followed by 7 consecutive injections of a single urine sample 143 
(QC-200 in Figure 1). The manipulations of the column temperature and the sample tray 144 
temperature were carried out by programmed LC methods on a new ZIC-pHILIC column in a 145 
sequence of (CT10, Std, CT40, ST5 and ST20) and the mobile phases and the columns were 146 
manually changed according to the protocol (Table 1). It should be aware that some 147 
parameter setting manipulations in this study were beyond the definition of routine 148 
robustness test, the main purpose was to stimulate the possible condition deviations in 149 
inter-batch analysis and evaluate the response of this HILIC-HRMS method to the changes. 150 
2.4 Data processing 151 
The Xcalibur raw data was converted into .mzXML files using ProteoWizard and imported 152 
into the MZMine 2.10 [28] for peak extraction and alignment. The detailed procedure and 153 
the parameter settings were the same as in our previous study [29] except for retention 154 
time tolerance window in alignment. Considering the possibility of significant changes in 155 
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retention time for some metabolites, the tolerance window was enlarged to 20% for 156 
alignment of the samples measured under varying LC conditions. The output .CSV file was 157 
imported into an in-house macro (Microsoft Excel 2010) for subtraction of the signals from 158 
blank injections. Putative annotation was also conducted in the macro by searching the 159 
accurate mass of M±H with a tolerance window of 3 ppm in our in-house database.[16] In 160 
biomarker discovery studies the US Food and Drug Administration (FDA) guidance allows up 161 
to 30% relative standard deviation (RSD) for signal variation among QC samples and Dunn et 162 
al suggested 20% for RPLC-HRMS. [30] In this study considering relatively poor 163 
chromatographic stability of HILIC compared to RPLC, we chose 25% RSD as the acceptance 164 
tolerance for signal variation. In order to assess the unrepeatability caused by sample 165 
preparation and data acquisition in this method, no RSD filter was applied on signal 166 
variation in data analysis for reliability evaluation.  167 
2.5 Statistical analysis  168 
SIMCA version 14.0 (Umetrics, Sweden) was used for MVA including PCA and OPLS. In order 169 
to prevent the model being dominated by several highly abundant urinary metabolites (e.g. 170 
creatinine and hippurate in ESI positive and negative mode respectively), unit variance (UV) 171 
scaling was used for all PCAs, but for OPLS Pareto scaling was used to facilitate the discovery 172 
of the spiked “biomarkers” (isotope labelled AAs) in the loading plot. No data normalisation 173 
and transformations were performed because all the samples were prepared from one 174 
single urine sample. Statistical functions in Microsoft Excel 2010 were used for basic 175 
calculations e.g. RSD and R2 value in linear regression analysis. 176 
3 Results and discussion 177 
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3.1 Evaluation of the technical variations in sample preparation and data acquisition 178 
A reliable LC-MS method for untargeted metabolite profiling is expected to determine 179 
biological variations among samples as opposed to technical variations which are inevitably 180 
introduced by sample preparation and data acquisition. Although this study might seem 181 
rather contrived it is designed to illustrate in a simple fashion the steps that occur in a 182 
typical LC-MS based metabolomics study and illustrate how variations might arise which 183 
could confuse data interpretation. As shown in Figure 1, in order to test the technical 184 
variations in the current analytical method, replicate urine samples were prepared with 185 
varied total volumes or dilution factors and one of the QC-200 samples was injected 17 186 
times throughout the whole run sequence. The LC-MS data generated was processed for the 187 
statistical analysis which followed. After removing the background signals from the blanks, 188 
2754 and 3017 LC-MS features were detected in the samples in the ESI positive and negative 189 
modes respectively. PCA was performed using the combined dataset without any filtration 190 
according to signal repeatability among QC injections (QCI). It can be observed in Figure 2A 191 
that the samples are primarily classified along the first principal component (PC1) 192 
representing dilution factor and the first four QCIs are clearly apart from others with the 193 
same urine dilution factor 5. After excluding the first four QCIs, in Figure 2B the clustering of 194 
each group was improved no marked separation of the samples with a dilution factor of 5 195 
can be observed. Compared to RPLC, HILIC is considered to require more time for system 196 
equilibration in gradient elution which is usually achieved by consecutively injecting a single 197 
QC sample prior to measurement of real samples. [25, 30] In the current case, four 198 
consecutive injections of a QC sample appear necessary for sufficient equilibration of this 199 
HILIC-HRMS system. In order to further distinguish the variations caused by sample 200 
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preparation and instrument instability, as shown in Figure 2C the PCA score plot was 201 
generated by only using the samples prepared with dilution factor of 5. Low R2X (0.375) and 202 
Q2 (0.307) scores were obtained by a combination of PC1 and PC2 indicating a poor fit for 203 
the model. This can be explained by the poor correlations in this dataset which can be 204 
attributed to the high similarity of LC-MS data for these samples. Regardless of the poor fit 205 
of the model, it still can be seen in Figure 2C that the QCIs distribute along  PC1 in a clear 206 
run time dependent manner and they are generally separated from most of other samples 207 
by the PC2. This observation implies that the LC-MS signal drift appears to be producing 208 
more serious technical variation than the sample preparation for the method. Interestingly, 209 
however, the opposite observation is reflected in Figure 2D. The samples prepared in the 210 
same way (QC-200: urine dilution factor=5 and total volume=1ml) generated more 211 
unrepeatable signals (RSD>25%) than multiple injections of a single sample (QCIs) even 212 
including the first four injections. Moreover, this number increased when a variable of urine 213 
volume, was used in the sample preparation but no clear classification can be observed in 214 
Figure 2C according to this variable. This phenomenon might be explained by the fact that 215 
MVA is more applicable for detection of systematic correlation/variation (dilution 216 
factors/signal drifting with time in the current case) rather than random deviation (sample 217 
preparation). Actually many LC-MS signals with poor RSDs among the QC-200 samples 218 
showed low but reproducible responses among QCIs (highlighted in green for the RSD% 219 
values in ESI.2) indicating that they are produced by low-abundance components in urine 220 
and can be reproducibly detected by this HILIC-HRMS platform and thus the variations are 221 
introduced by the sample preparation. Therefore, as addressed by Dunn et al  [31], multiple 222 
individual QC samples (≥3) should be prepared and measured along with real samples not 223 
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only for monitoring the system stability of the instruments but also for assessing deviations 224 
for individual metabolites introduced in the sample preparation.   225 
The samples prepared with varied total volumes or dilution factors showed a slight 226 
difference in the number of LC-MS signals with RSD below 25% except that a smaller 227 
dilution factor does improve the reproducibility in the measurement of low-abundance 228 
components in urine (see ESI.3A). It should be noticed that many of these were putatively 229 
annotated as oligopeptides (2-5 amino acids) based on accurate mass (highlighted in yellow 230 
for the RSD% values in ESI.2). The major concern for samples prepared with a small dilution 231 
factor is saturation of the mass spectrometry detection of high-abundance components in 232 
urine. Creatinine and hippurate were detected by the current method as the largest 233 
chromatographic peaks in ESI positive and negative mode respectively. By comparing the 234 
peak areas, significant differences could be observed according to the dilution factors but 235 
the correlation coefficient was only valid for hippurate and not for creatinine (ESI.3B) which 236 
indicates the reliability of this method for comparative analysis but a limitation in absolute 237 
quantification. This observation suggests that less dilution of urine may facilitate LC-MS 238 
detection of the low-abundance urinary metabolites while reducing the reliability of the 239 
absolute quantification for the high-abundance metabolites. 240 
3.2 Method suitability evaluation using OPLS model 241 
The metabolic perturbation caused by local pathogenicity (especially for early detection of 242 
chronic diseases such as cancer) on metabolome of human beings could be subtle thus this 243 
change in the metabolic signatures of clinical samples usually cannot be visualised by using 244 
unsupervised MVA (e.g. PCA). Therefore, supervised MVA (e.g. OPLS-DA) is often employed 245 
in clinical metabolomics studies. Here, we demonstrated the suitability of the current HILIC-246 
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HRMS method in combination with OPLS analysis. As shown in Figure.1, ACN solutions 247 
containing sixteen isotope labelled (13C and 15N) amino acids were spiked into the urine 248 
samples with varying concentrations and together with the non-spiked urine samples (QC-249 
200) the LC-MS data from these samples was used to prepare the MVA plots are shown in 250 
Figure 3. The DF1 samples were found as outliers in the original PCA plot because of the 251 
high concentration of spiked isotope labelled amino acids and thus they were excluded in 252 
the following analysis. As expected and shown in Figure 3A, under the dominating effect of 253 
the urinary metabolome the PCA model was unable to distinguish the subtle differences in 254 
the dataset caused by the spiking of isotope labelled amino acids. In contrast as shown in 255 
Figure 3B, the OPLS model accurately classified the samples according to the concentrations 256 
of the isotope labelled amino acids, even with small fold-changes, along the X axis (the 257 
correlated principal component). Large variations along the Y axis (the first orthogonally 258 
correlated principal component) can be observed in each group. This outcome was validated 259 
in comparison with the PCA model generated using the samples spiked into water thus 260 
removing the masking effect of the urinary metabolome. As shown in Figure 3C, the samples 261 
were naturally classified by the dilution factors for the isotope labelled amino acids along 262 
PC1. Figure 3D shows the loading plot of the OPLS model. The LC-MS signals generated by 263 
isotope labelled amino acids were identified in both ESI positive and negative modes and 264 
represented as solid red marks in the figure. As can be seen all of them associate with the X 265 
axis in a positive direction indicating highly positive correlation with the Y-variable (dilution 266 
factor). Due to the fact that the labelled amino acid mixture was extracted from blue-green 267 
algae; it contains some metabolites which are not naturally present in human urine, and 268 
many other hollow green marks can be also seen on the X axis showing highly positive 269 
correlation with dilution factor. On the other hand, the metabolites present in both human 270 
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urine and the blue-green algal extract exhibit a noticeable deviation along the Y axis such as 271 
uric acid and citric acid (solid green marks in Figure 3D). Significant ion suppression for the 272 
heavy isotope labelled amino acids by the corresponding light isotope signals in urine can be 273 
observed when comparing their peak areas with the same dilution factors in water (ESI.4). 274 
Apart from that observation, the correlation of the signal of each isotope labelled amino 275 
acid to dilution factor was generally good (the mean R2 value calculated in linear regression 276 
analysis for all the isotope labelled amino acids was 0.989 ± 0.018 and 0.988 ± 0.027 in ESI 277 
negative and positive modes, respectively). However, considering the complexity of the 278 
urine metabolome for real clinical samples, care should be taken with regard to ion 279 
suppression of low intensity signals during the selection of biomarker candidates. 280 
3.3 Robustness evaluation for LC parameters 281 
Reproducible and reliable LC performance of intra- and more importantly inter-batch 282 
analysis is the key for chromatographic alignment of data during processing. As described in 283 
Table 1, four primary LC parameters were manipulated to simulate possible inter-batch 284 
deviations in LC conditions. The responses of the HILIC-HRMS method were demonstrated 285 
by PCA of the retention times of the 200 most intense LC-MS signals putatively annotated as 286 
real metabolites in ESI positive and negative ion mode. The retention times were manually 287 
defined based on the metabolite annotation in a few cases when alignment failed to find 288 
the peaks. Based on the distances to the cluster of usual standard conditions (Std) locating 289 
in the middle of the plot in Figure 4A, the order of effect on retention time from minor to 290 
significant is: sample tray temperature (ST20 and ST5) < mobile phase pH 9.5 (pH 9.5) ≈ 291 
column temperature 10oC (CT10) < using different columns (used and Hused) << mobile 292 
phase pH 8.5 (pH 8.5) ≈ column temperature 40oC (CT40). In general according to the 293 
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theoretical basis of reversed phase liquid chromatography, high temperature will increase 294 
the diffusion rates of solutes thus reducing partitioning into the stationary phase and thus 295 
reducing their retention times. However, this is not always the case in HILIC mode. [32] In 296 
the case of the two examples shown in Figure 4B, marked retention time changes in 297 
opposite directions could be observed for different metabolites under the conditions of 298 
CT40 (red marks) and pH 8.5 (blue marks). The detailed chromatographic mechanisms 299 
behind this observation will not be discussed here but will be explored in a subsequent 300 
study. Excluding these two extreme conditions, only 6 out of 400 individual LC-MS signals 301 
showed RSD in their retention times > ± 5% with the a maximum of ± 5.57% indicating good 302 
robustness of this HILIC method and most valuably only a small variation in retention times 303 
(4 out of 400 showed RSD > ± 5% with a maximum of ± 5.46%) was achieved on three 304 
different ZICpHILIC columns (ESI.5). Unlike column temperature and mobile phase pH, the 305 
reproducibility of chromatographic performance between different batch-numbered 306 
commercial HILIC columns is beyond the control of the researchers who perform LC-MS 307 
experiments. The current observations provide evidence that highly reproducible 308 
chromatographic performance can be achieved on the ZICpHILIC phase over multiple 309 
columns thus allowing alignment of chromatographic data run on columns columns with 310 
different batch numbers without applying retention time normalisation algorithms.  311 
4 Conclusion 312 
There is a lack of clear protocols for assessing the reliability and robustness of LC-MS 313 
methods for untargeted metabolomics. It is crucial that such methods are reliable and 314 
robust otherwise bioinformatics methods applied to the data generated will simply highlight 315 
unstable elements in the methodology due to variations in sample preparation, 316 
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chromatography and MS instrument response. In this study, human urine as matrix, we 317 
investigated the reliability and suitability of a HILIC-HRMS (ZIC-pHILIC-Exactive Orbitrap) 318 
method for untargeted metabolite profiling of human urine. From the study it is possible to 319 
summarise some key points with regard to achieving reliable data with this method. The 320 
HILIC-HRMS method required four QC injections to reach equilibrium conditions. Data 321 
variability introduced by sample preparation is larger than that produced during data 322 
acquisition by HILIC-HRMS for low-abundance urinary components. Therefore, multiple QC 323 
samples should be prepared from a single pooled sample and measured in parallel with real 324 
samples to evaluate the variations introduced in sample preparation [31],this is more even 325 
necessary for clinical samples derived from blood and tissue because more complicated 326 
sample preparation is involved. [30, 33] The subtle variation in datasets determined by the 327 
small fold changes of spiked isotope labelled amino acids was accurately observed by an 328 
OPLS model indicating the power of orthogonal multivariate treatments for observing subtle 329 
differences among samples. However, the analyst should be aware of potential matrix 330 
suppression effects on low abundance components. The pH of the mobile phase only has a 331 
strong effect if it falls below pH 9.0 and thus pH unadjusted ammonium carbonate which 332 
has a pH of ca 9.1 can be used. Column temperature should be controlled for this HILIC-333 
HRMS method because dramatic changes in retention times were observed for some 334 
metabolites with elevated column temperature.  It was demonstrated that highly 335 
reproducible chromatographic performance can be achieved on this polymer based 336 
zwitterionic stationary phase in HILIC mode between different columns thus potentially 337 
allowing data combination following column replacement in long term inter-batch analysis.  338 
 339 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
Acknowledgment 340 
We acknowledge Scottish Life Sciences Alliance for support for mass spectrometry 341 
equipment. 342 
References 343 
[1] J.L. Spratlin, N.J. Serkova, S.G. Eckhardt, Clinical applications of metabolomics in oncology: a 344 
review, Clinical cancer research : an official journal of the American Association for Cancer Research, 345 
15 (2009) 431-440. 346 
[2] A. Roux, D. Lison, C. Junot, J.F. Heilier, Applications of liquid chromatography coupled to mass 347 
spectrometry-based metabolomics in clinical chemistry and toxicology: A review, Clinical 348 
biochemistry, 44 (2011) 119-135. 349 
[3] S. Becker, L. Kortz, C. Helmschrodt, J. Thiery, U. Ceglarek, LC-MS-based metabolomics in the 350 
clinical laboratory, Journal of chromatography. B, Analytical technologies in the biomedical and life 351 
sciences, 883-884 (2012) 68-75. 352 
[4] A. D'Alessandro, B. Giardina, F. Gevi, A.M. Timperio, L. Zolla, Clinical metabolomics: the next 353 
stage of clinical biochemistry, Blood transfusion = Trasfusione del sangue, 10 Suppl 2 (2012) s19-24. 354 
[5] C. Baumgartner, A Clinical Metabolomics Strategy to Discover New Biomarkers in Complex 355 
Disease: An Overview, Biomedizinische Technik. Biomedical engineering, DOI 10.1515/bmt-2013-356 
4305(2013). 357 
[6] T. Zhang, D.G. Watson, A short review of applications of liquid chromatography mass 358 
spectrometry based metabolomics techniques to the analysis of human urine, The Analyst, 140 359 
(2015) 2907-2915. 360 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
[7] H. Peretz, D.G. Watson, G. Blackburn, T. Zhang, A. Lagziel, M. Shtauber-Naamati, T. Morad, E. 361 
Keren-Tardai, V. Greenshpun, S. Usher, H. Shalev, D. Landau, D. Levartovsky, Urine metabolomics 362 
reveals novel physiologic functions of human aldehyde oxidase and provides biomarkers for typing 363 
xanthinuria, Metabolomics, 8 (2012) 951-959. 364 
[8] M. Mraz, O. Hurba, J. Bartl, Z. Dolezel, A. Marinaki, L. Fairbanks, B. Stiburkova, Modern diagnostic 365 
approach to hereditary xanthinuria, Urolithiasis, 43 (2015) 61-67. 366 
[9] D.K. Trivedi, R.K. Iles, Do not just do it, do it right: urinary metabolomics -establishing clinically 367 
relevant baselines, Biomed Chromatogr, 28 (2014) 1491-1501. 368 
[10] M.M. Khamis, D.J. Adamko, A. El-Aneed, Mass spectrometric based approaches in urine 369 
metabolomics and biomarker discovery, Mass Spectrom Rev, DOI 10.1002/mas.21455(2015). 370 
[11] A. Sreekumar, L.M. Poisson, T.M. Rajendiran, A.P. Khan, Q. Cao, J. Yu, B. Laxman, R. Mehra, R.J. 371 
Lonigro, Y. Li, M.K. Nyati, A. Ahsan, S. Kalyana-Sundaram, B. Han, X. Cao, J. Byun, G.S. Omenn, D. 372 
Ghosh, S. Pennathur, D.C. Alexander, A. Berger, J.R. Shuster, J.T. Wei, S. Varambally, C. Beecher, A.M. 373 
Chinnaiyan, Metabolomic profiles delineate potential role for sarcosine in prostate cancer 374 
progression, Nature, 457 (2009) 910-914. 375 
[12] N. Cernei, Z. Heger, J. Gumulec, O. Zitka, M. Masarik, P. Babula, T. Eckschlager, M. Stiborova, R. 376 
Kizek, V. Adam, Sarcosine as a potential prostate cancer biomarker--a review, International journal 377 
of molecular sciences, 14 (2013) 13893-13908. 378 
[13] H.G. Gika, G.A. Theodoridis, R.S. Plumb, I.D. Wilson, Current practice of liquid chromatography-379 
mass spectrometry in metabolomics and metabonomics, J Pharm Biomed Anal, 87 (2014) 12-25. 380 
[14] H.G. Gika, I.D. Wilson, G.A. Theodoridis, LC-MS-based holistic metabolic profiling. Problems, 381 
limitations, advantages, and future perspectives, Journal of chromatography. B, Analytical 382 
technologies in the biomedical and life sciences, 966 (2014) 1-6. 383 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
[15] P.D. Rainville, G. Theodoridis, R.S. Plumb, I.D. Wilson, Advances in liquid chromatography 384 
coupled to mass spectrometry for metabolic phenotyping, Trac-Trend Anal Chem, 61 (2014) 181-191. 385 
[16] T. Zhang, D.J. Creek, M.P. Barrett, G. Blackburn, D.G. Watson, Evaluation of Coupling Reversed 386 
Phase, Aqueous Normal Phase, and Hydrophilic Interaction Liquid Chromatography with Orbitrap 387 
Mass Spectrometry for Metabolomic Studies of Human Urine, Anal Chem, 84 (2012) 1994-2001. 388 
[17] R. Zhang, D.G. Watson, L. Wang, G.D. Westrop, G.H. Coombs, T. Zhang, Evaluation of mobile 389 
phase characteristics on three zwitterionic columns in hydrophilic interaction liquid chromatography 390 
mode for liquid chromatography-high resolution mass spectrometry based untargeted metabolite 391 
profiling of Leishmania parasites, J Chromatogr A, 1362 (2014) 168-179. 392 
[18] K. Contrepois, L. Jiang, M. Snyder, Optimized Analytical Procedures for the Untargeted 393 
Metabolomic Profiling of Human Urine and Plasma by Combining Hydrophilic Interaction and 394 
Reverse-Phase Liquid Chromatography - Mass Spectrometry, Molecular & cellular proteomics : MCP, 395 
DOI 10.1074/mcp.M114.046508(2015). 396 
[19] S.U. Bajad, W. Lu, E.H. Kimball, J. Yuan, C. Peterson, J.D. Rabinowitz, Separation and 397 
quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-398 
tandem mass spectrometry, Journal of chromatography. A, 1125 (2006) 76-88. 399 
[20] D.P. Kloos, H. Lingeman, W.M. Niessen, A.M. Deelder, M. Giera, O.A. Mayboroda, Evaluation of 400 
different column chemistries for fast urinary metabolic profiling, Journal of chromatography. B, 401 
Analytical technologies in the biomedical and life sciences, 927 (2013) 90-96. 402 
[21] D.L. Callahan, D. De Souza, A. Bacic, U. Roessner, Profiling of polar metabolites in biological 403 
extracts using diamond hydride-based aqueous normal phase chromatography, J Sep Sci, 32 (2009) 404 
2273-2280. 405 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
19 
 
[22] H.G. Gika, G.A. Theodoridis, J.E. Wingate, I.D. Wilson, Within-day reproducibility of an HPLC-MS-406 
Based method for metabonomic analysis: Application to human urine, J Proteome Res, 6 (2007) 407 
3291-3303. 408 
[23] T.J. Demetrowitsch, B. Petersen, J.K. Keppler, A. Koch, S. Schreiber, M. Laudes, K. Schwarz, 409 
Validation of a two-step quality control approach for a large-scale human urine metabolomic study 410 
conducted in seven experimental batches with LC/QTOF-MS, Bioanalysis, 7 (2015) 103-112. 411 
[24] P.A. Guy, I. Tavazzi, S.J. Bruce, Z. Ramadan, S. Kochhar, Global metabolic profiling analysis on 412 
human urine by UPLC-TOFMS: issues and method validation in nutritional metabolomics, Journal of 413 
chromatography. B, Analytical technologies in the biomedical and life sciences, 871 (2008) 253-260. 414 
[25] E.J. Want, I.D. Wilson, H. Gika, G. Theodoridis, R.S. Plumb, J. Shockcor, E. Holmes, J.K. Nicholson, 415 
Global metabolic profiling procedures for urine using UPLC-MS, Nature protocols, 5 (2010) 1005-416 
1018. 417 
[26] D.Q. Tang, L. Zou, X.X. Yin, C.N. Ong, HILIC-MS for metabolomics: An attractive and 418 
complementary approach to RPLC-MS, Mass Spectrom Rev, DOI 10.1002/mas.21445(2014). 419 
[27] E. Daskalaki, G. Blackburn, G. Kalna, T. Zhang, N. Anthony, D.G. Watson, A study of the effects of 420 
exercise on the urinary metabolome using normalisation to individual metabolic output, Metabolites, 421 
5 (2015) 119-139. 422 
[28] T. Pluskal, S. Castillo, A. Villar-Briones, M. Oresic, MZmine 2: modular framework for processing, 423 
visualizing, and analyzing mass spectrometry-based molecular profile data, BMC bioinformatics, 11 424 
(2010) 395. 425 
[29] T. Zhang, D.G. Watson, L.J. Wang, M. Abbas, L. Murdoch, L. Bashford, I. Ahmad, N.Y. Lam, A.C.F. 426 
Ng, H.Y. Leung, Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry 427 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
20 
 
Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery, Plos One, 8 428 
(2013). 429 
[30] W.B. Dunn, D. Broadhurst, P. Begley, E. Zelena, S. Francis-McIntyre, N. Anderson, M. Brown, J.D. 430 
Knowles, A. Halsall, J.N. Haselden, A.W. Nicholls, I.D. Wilson, D.B. Kell, R. Goodacre, Procedures for 431 
large-scale metabolic profiling of serum and plasma using gas chromatography and liquid 432 
chromatography coupled to mass spectrometry, Nature protocols, 6 (2011) 1060-1083. 433 
[31] W.B. Dunn, I.D. Wilson, A.W. Nicholls, D. Broadhurst, The importance of experimental design 434 
and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans, 435 
Bioanalysis, 4 (2012) 2249-2264. 436 
[32] Z.G. Hao, B.M. Xiao, N.D. Weng, Impact of column temperature and mobile phase components 437 
on selectivity of hydrophilic interaction chromatography (HILIC), J Sep Sci, 31 (2008) 1449-1464. 438 
[33] H. Gika, G. Theodoridis, Sample preparation prior to the LC-MS-based 439 
metabolomics/metabonomics of blood-derived samples, Bioanalysis, 3 (2011) 1647-1661. 440 
 441 
 442 
Figure legends 443 
Figure.1 Preparation of a series of urine samples for HILIC-HRMS method reliability and 444 
robustness evaluation. One of the QC-200 samples was used for QC injection (named as QCI), 445 
7 times before running other samples and followed by every 10 samples and 5 times again 446 
after the whole sequence. DF=dilution factor, TV=total volume, AA=amino acid and 447 
ACN=acetonitrile. 448 
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Figure.2 HILIC-HRMS method technical variation evaluation using the samples prepared with 449 
varied urine volumes and dilution factors. The colour keys are shown at top-right in each 450 
figure and described in section 2.2 and Figure.1. A: PCA score plot of all the urine samples 451 
and the QC injections (QCI). B: PCA score plot of without the first four QCIs. C: PCA score 452 
plot of only the samples with urine dilution factor 5 including QCI5-17. D: column chart of 453 
the numbers of the LC-MS signals with RSD beyond 25% in peak area generated by QCIs, 454 
200-QC samples and all the samples with urine dilution factor 5 including 50, 400 and 200-455 
QC. 456 
Figure.3 HILIC-HRMS method reliability evaluation using the samples with varied 457 
concentrations of 13C and 15N isotope labelled amino acids. The colour keys are shown at 458 
top-right in each figure and described in section 2.1 and Figure.1. A: PCA score plot of the 459 
urine samples with and without spiked isotope labelled amino acids. B: OPLS score plot of 460 
the same samples in A. C: PCA score plot of water samples with spiked isotope labelled 461 
amino acids. D: OPLS loading plot of urinary metabolites vs. dilution factors of spiked 462 
isotope labelled amino acids (X variables: metabolites and Y variables: dilution factors). The 463 
sixteen identified isotope labelled amino acids (in both ESI positive and negative modes) are 464 
marked in solid red and the other three metabolites mentioned in the text are marked in 465 
solid green and are clearly orthogonal to the specified Y variables since they are also present 466 
in the urinary matrix. 467 
Figure.4 HILIC-HRMS method robustness test: LC parameters (see Table.1). A: PCA score plot 468 
of the replicate injections with varied LC parameters. The colour keys are shown at top-right 469 
in the figure. B: Two examples for the metabolites showing dramatic but opposite changes 470 
in retention time under the conditions of CT40 (in red) and pH8.5 (in blue). 471 
Highlights 
1. The technical variations introduced by sample preparation was found more significant than the current HILIC-HRMS platform after 
multivariate (PCA) and univariate (RSD) analysis of the urine samples (injections) prepared with varied urine volumes and dilution 
factors. 
2. The suitability of the current HILIC-HRMS method to clinical metabolomics was demonstrated by supervised multivariate analysis (OPLS 
model) of the urine samples spiked with isotope labelled amino acids at varied concentrations. 
3. Several key LC parameters were investigated in respect of LC stability for inter-batch analysis and high reproducibility of 
chromatographic performance was observed with this polymer based zwitterionic stationary phase in HILIC mode. 
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